| Document |
Document Title |
|
WO/2022/266236A1 |
The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmace...
|
|
WO/2022/258044A1 |
Provided are a pyrrolopyridinone compound as represented by formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutical preparation, a pharmaceutical composition and the use of the compound, wherein the compound can ...
|
|
WO/2022/261154A1 |
The present invention provides compounds of the formula where R1, R2, R3, R4a, R4b, R4c, R5, R6, X, Y, and Z are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically ac...
|
|
WO/2022/260117A1 |
An organic electroluminescent element (1) includes: an anode (3); a cathode (4); a light-emitting layer (5) that is included between the anode (3) and the cathode (4); and a first layer (61) that is included between the anode (3) and the...
|
|
WO/2022/261159A1 |
The present disclosure relates to tricyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
|
|
WO/2022/261160A1 |
The present disclosure relates to tricyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
|
|
WO/2022/260119A1 |
A compound which is represented by general formula (1). In general formula (1), CN represents a cyano group; each of D11 and D12 independently represents a group that is represented by general formula (11), general formula (12) or genera...
|
|
WO/2022/254965A1 |
This compound represented by the general formula is a light-emitting material having a short lifetime of delayed fluorescence. Two or three among R1-R4 are donor groups, at least one of which is a ring-fused indol-1-yl group, one or two ...
|
|
WO/2022/256459A1 |
Provided herein are KRAS modulating compounds, such as compounds of Formula (I), (II), (III), or (X), or pharmaceutically acceptable salts, solvates, stereoisomers, atom labelled, or tautomers of any of the foregoing, useful for modulati...
|
|
WO/2022/253341A1 |
Disclosed are 2, 8-diazaspiro [4.5] decane compounds, including (pyrido [3, 4-d] pyrimidin-4-yl) -2, 8-diazaspiro [4.5] decane compounds, (2, 6-naphthyridin-1-yl) -2, 8-diazaspiro [4.5] decane compounds, and (1, 7-naphthyridin-4-yl) -2, ...
|
|
WO/2022/247641A1 |
Provided are a new class of compounds having a WEE1 inhibitory effect and as represented by formula I, and the use thereof in the preparation of a drug.
|
|
WO/2022/251224A1 |
Compounds of general Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive ...
|
|
WO/2022/251306A1 |
The present disclosure provides, inter alia, a compound having the structure of Formula (1): Also provided are compositions containing a pharmaceutically acceptable carrier and one or more compounds according to the present disclosure. F...
|
|
WO/2022/247760A1 |
Disclosed are compounds of formulae (I) and (II) or a pharmaceutically acceptable salt, a prodrug, a tautomer or a stereoisomer thereof and a solvate thereof; and a method for preparing the compounds of formulae (I) and (II), and a pharm...
|
|
WO/2022/249972A1 |
The present invention addresses the problem of providing: a photoelectric conversion element which has excellent photoelectric conversion efficiency, while achieving excellent suppression of electric field strength dependence of the phot...
|
|
WO/2022/246576A1 |
Camptothecin analogues of Formula (I) and conjugates comprising the camptothecin analogues are described. The camptothecin analogues and conjugates may be used as therapeutic agents, particularly in the treatment of cancer, an autoimmune...
|
|
WO/2022/248885A2 |
This invention relates to compounds that may be useful for inhibiting RAS proteins. More specifically, this invention relates to compounds for inhibiting a broad spectrum of KRAS mutant proteins. The compounds of the invention may theref...
|
|
WO/2022/242753A1 |
The present disclosure relates to a pharmaceutically acceptable salt of a pyrazoloheteroaryl derivative and a crystal form thereof. In particular, the present disclosure relates to a pharmaceutically acceptable salt of a compound represe...
|
|
WO/2022/242438A1 |
The present invention relates to the technical field of chemical synthetics, and relates to a texaphyrin-folate conjugate and a preparation method therefor and an application thereof. The texaphyrin-folate conjugate contains a conjugate ...
|
|
WO/2022/242658A1 |
Disclosed are a salt form and a crystal form of a heterocyclic substituted purinone derivative and a preparation method therefor. Specifically disclosed are a salt form and a crystal form of a compound of formula (I) and a preparation me...
|
|
WO/2022/237178A1 |
The present invention relates to a bicyclic heteroaryl derivative and a preparation method therefor and a use thereof in medicine. Specifically, the present invention relates to a bicyclic heteroaryl derivative represented by formula (AI...
|
|
WO/2022/237407A1 |
The present invention relates to an organic compound represented by a formula I, wherein Ar1 and Ar2 are groups such as an aromatic ring or a heteroaromatic ring introduced on the outside of a molecule, and R1 to R10 are the same as or d...
|
|
WO/2022/237890A1 |
An azepine-type fused ring compound and a pharmaceutical use thereof. Specifically, involved are an azepine-type fused ring compound shown in general formula (I), a preparation method therefor, a pharmaceutical composition comprising sam...
|
|
WO/2022/235864A1 |
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
|
|
WO/2022/233801A1 |
Methods for preparing the Bruton's Tyrosine Kinase ("BTK") inhibitor compound 2-{3'-hydroxymethyl-1-methyl-5-[5-((S)-2-methyl-4-oxetan-3-y
l-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4'
]bipyridinyl-2'-yl}-7,7-dimethyl-3,4,...
|
|
WO/2022/233442A1 |
The present invention relates to tricyclic heterocycles. These heterocyclic compounds are useful as TEAD binders and/or inhibitors of YAP-TEAD and TAZ-TEAD protein-protein interaction or binding and for the prevention and/or treatment of...
|
|
WO/2022/235870A1 |
The invention features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
|
|
WO/2022/235866A1 |
The disclosure features compounds, or pharmaceutically acceptable salts thereof, alone and in combination with other therapeutic agents, pharmaceutical compositions, and protein conjugates thereof, capable of modulating biological proces...
|
|
WO/2022/235945A1 |
This disclosure relates to compounds of Formula (A): BTK— L— DSM (A) or a pharmaceutically acceptable salt thereof, wherein DSM is a degradation signaling moiety that is covalently attached to the linker L, L is a linker that covalen...
|
|
WO/2022/230793A1 |
The purpose of the present invention is to provide a compound that promotes the maintenance and multiplication of hematopoietic stem cells, and is useful in the cultivation and similar of hematopoietic stem cells that can be used in hema...
|
|
WO/2022/228568A1 |
Provided is a pyridino- or pyrimido-cyclic compound having an inhibitory effect on a KRAS gene mutation, or a pharmaceutically acceptable salt, a stereoisomer or a solvate thereof, wherein the structure of the compound is as shown in for...
|
|
WO/2022/232332A1 |
The present disclosure provides compounds useful for the inhibition of KRAS G12D. The compounds have a general Formula I: (I) wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical composition...
|
|
WO/2022/228365A1 |
A derivative of a six-membered heteroaromatic urea ring represented by formula (I) and an application thereof in the preparation of a drug for treating diabetic nephropathy or hypertensive nephropathy.
|
|
WO/2022/228399A1 |
The present invention relates to the technical field of medicine, in particular to a tricyclic USP1 inhibitor compound, a pharmaceutically acceptable salt thereof, an ester, a deuterated substance or a stereoisomer thereof, a pharmaceuti...
|
|
WO/2022/229234A1 |
The present invention relates to nitrogenous hetetocyclic compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
|
|
WO/2022/229102A1 |
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.
|
|
WO/2022/222951A1 |
The present invention relates to a substituted aromatic condensed ring derivative, a preparation method therefor and an application of a pharmaceutical composition comprising the derivative in medicine. Specifically, the present inventio...
|
|
WO/2022/221939A1 |
Compounds, compositions and their use in the treatment of a proliferative disease or condition such as a said proliferative disease or disorder is associated with a RAF gene mutation and/or a RAS gene mutation. The compounds disclosed ar...
|
|
WO/2022/218970A2 |
A conjugate of formula (I): L - (DL)p, wherein L is a Ligand unit (i.e., a targeting agent), p is from 1 to 20, DL is a Drug Linker unit of formula (I'); RLL is a linker for connection to the Ligand Unit, D represents D1; D' represents D'1.
|
|
WO/2022/218856A1 |
The present invention relates to new compounds of formula (I') as sigma ligands having a great affinity for sigma receptors, sigma-1 receptor (σ1) and/or sigma-2 receptor (σ2). The present invention also refers to the process for the p...
|
|
WO/2022/220227A1 |
Provided is a tetrahydropyridopyrimidine compound which has Axl inhibitory activity and selectively inhibits Axl over Mer.
|
|
WO/2022/221642A1 |
The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided...
|
|
WO/2022/217859A1 |
Disclosed in the present invention are a bisindole alkaloid compound, and a synthesis method therefor and the use thereof. The compound has a structure as shown in formula I, wherein R1 is independently selected from C1-C4 alkoxy or hydr...
|
|
WO/2022/216762A1 |
Provided herein are acyclic oxazepinyl compounds useful in the treatment on cancers.
|
|
WO/2022/214102A1 |
Provided in the present invention is a compound acting as a KRAS G12D inhibitor; specifically provided in the present invention is a compound of the structure shown in the following formula (I), or an optical isomer, a pharmaceutically a...
|
|
WO/2022/216961A1 |
In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to compounds and methods for activating NAMPT in a subject. The compounds described herein are ...
|
|
WO/2022/217042A1 |
The invention provides naphthyl-substituted quinolin-4(1H)-ones and related compounds, pharmaceutical compositions, their use for inhibiting K-Ras G12D activity, and their use in the treatment of medical disorders, such as cancer.
|
|
WO/2022/213854A1 |
The present invention relates to a series of carbazole derivative and a use thereof. The structural formula of the carbazole derivative is as shown in formula (I). The present carbazole derivative has high stability and triplet energy le...
|
|
WO/2022/213896A1 |
The present invention provides a quinoxaline compound, a preparation method, and a pharmaceutical application thereof, and particularly relates to a quinoxaline compound having PAR4 antagonistic activity and a preparation method therefor...
|
|
WO/2022/207752A1 |
A compound comprising the formula (I), wherein each X1 is independently selected from C, N, O and S; each Y is independently selected from C and N; Z1 is independently selected from C and N; each X1 may independently be unsubstituted, or...
|
